1. Signaling Pathways
  2. Epigenetics
  3. Histone Methyltransferase

Histone Methyltransferase

Methyltransferase

Histone modifications play critical roles in regulating both global and stage-specific gene expression. Methylation on histones H3K4, H3K36 and H3K79 is generally associated with gene activation, whereas methylation on histones H3K9 and H3K27 is generally associated with gene repression. Histone lysine methylation is dynamically regulated by site-specific methyltransferases and demethylases. EZH2 (the catalytic subunit of PRC2) is responsible for the methylation of H3K27 in cells.

DOT1L is a histone H3 lysine 79 methyltransferase whose inhibition increases the yield of induced pluripotent stem cells (iPSCs). EPZ-5676 is a potent and selective DOT1L inhibitor.

Crucial to PRC2 activity, the histone methyltransferase enhancer of zeste homolog 2 (EZH2) tri-methylates lysine 27 of histone 3 (H3K27me3), leading to chromatin condensation and transcriptional repression.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-156680
    TNG-462
    Inhibitor 99.91%
    TNG-462 is an orally active and selective PRMT5 inhibitor with anti-tumor activity against methylthioadenosine phosphorylase (MTAP) deficiency and/or methylthioadenosine (MTA) accumulation cancers.
    TNG-462
  • HY-101925
    CM-272
    Inhibitor 98.70%
    CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death.
    CM-272
  • HY-112445
    SGC3027
    Inhibitor 98.06%
    SGC3027 is a histone methyltransferase inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for PRMT7.
    SGC3027
  • HY-100034
    NSC 663284
    Inhibitor 99.29%
    NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC50 for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively. NSC 663284 inhibits NSD2 (IC50 of 170 nM) through a direct interaction with the catalytic SET domain (Kd of 370 nM).
    NSC 663284
  • HY-101512
    A-395
    Inhibitor 99.12%
    A-395 is an antagonist of polycomb repressive complex 2 (PRC2) protein-protein interactions that potently inhibits the trimeric PRC2 complex (EZH2-EED-SUZ12) with an IC50 of 18 nM.
    A-395
  • HY-107777
    LLY-283
    Inhibitor 99.22%
    LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity.
    LLY-283
  • HY-148419
    Ralometostat
    Inhibitor 98.89%
    TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research.
    Ralometostat
  • HY-18962
    AMI-1
    Inhibitor ≥98.0%
    AMI-1 is a potent, cell-permeable and reversible inhibitor of protein arginine N-methyltransferases (PRMTs), with IC50s of 8.8 μM and 3.0 μM for human PRMT1 and yeast-Hmt1p, respectively. AMI-1 exerts PRMTs inhibitory effects by blocking peptide-substrate binding.
    AMI-1
  • HY-18627A
    PFI-2 hydrochloride
    Inhibitor 99.48%
    PFI-2 ((R)-PFI-2 hydrochloride) hydrochloride is a potent and selective SET domain containing lysine methyltransferase 7 (SETD7) inhibitor. (R)-PFI-2 shows high inhibiting activity with IC50 value of 2.0  nM and (S)-PFI-2 shows inhibiting activity with IC50  value of 1.0  μM. PFI-2 hydrochloride can be used for the research of chronic kidney disease and inflammation response in the development of renal fibrosis.
    PFI-2 hydrochloride
  • HY-150190
    F5446
    Inhibitor 99.38%
    F5446 (Compound 1) is a selective small molecule inhibitor of SUV39H1 methyltransferase. F5446 decreases H3K9me3 deposition at the FAS promoter, increases Fas expression and increases colorectal carcinoma cell sensitivity to FasL-induced apoptosis in vitro. F5446 suppresses human colon tumor xenograft growth in vivo.
    F5446
  • HY-12970
    EPZ020411
    Inhibitor 98.07%
    EPZ020411 is a selective inhibitor of PRMT6 with an IC50 of 10 nM, has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 can be used for the research of cancer.
    EPZ020411
  • HY-109108A
    Valemetostat tosylate
    Inhibitor 99.84%
    Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC50 values <10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma.
    Valemetostat tosylate
  • HY-116522
    AR420626
    98.29%
    AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3) (IC50=117 nM). AR420626 has anti-inflammatory, anticancer and antidiabetic activities. AR420626 improves neurogenic diarrhea by inhibiting nAChR mediated neural pathways. AR420626 inhibits the growth of HepG2 xenografts and inhibits the proliferation of hepatoma cells by inducing apoptosis. AR420626 also suppresses allergic asthma and eczema and has the ability to activate GPR41 to increase Ca2+ signal-mediated glucose uptake and improve diabetes.
    AR420626
  • HY-103663
    MAK683
    Inhibitor 99.18%
    MAK683 is an embryonic ectoderm development (EED) inhibitor extracted from patent US20160176882 A1, compound example 2. MAK683 exhibits IC50s of 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay.
    MAK683
  • HY-141429A
    AS-99 TFA
    Inhibitor 99.15%
    AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.
    AS-99 TFA
  • HY-B1322A
    Amodiaquine
    Inhibitor 99.98%
    Amodiaquine (Amodiaquin), a 4-aminoquinoline class of antimalarial agent, is a potent and orally active histamine N-methyltransferase inhibitor. Amodiaquine is also a Nurr1 agonist and specifically binds to Nurr1-LBD (ligand binding domain) with an EC50 of ~20 μM. Anti-inflammatory effect.
    Amodiaquine
  • HY-130708
    UNC6852
    Inhibitor 99.09%
    UNC6852 is a selective polycomb repressive complex 2 (PRC2) degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a von Hippel-Lindau ligand, with an IC50 of 247 nM for EED.
    UNC6852
  • HY-139626
    EPZ-719
    Inhibitor 99.85%
    EPZ-719 is a selective, orally effective SETD2 inhibitor with an IC50 value of 0.005 μM. EPZ-719 has anticancer activity.
    EPZ-719
  • HY-15226
    AZ505
    Inhibitor 99.99%
    AZ505 is a potent and selective SMYD2 inhibitor with an IC50 of 0.12 μM.
    AZ505
  • HY-12970A
    EPZ020411 hydrochloride
    Inhibitor 98.15%
    EPZ020411 hydrochloride is a selective inhibitor of PRMT6 with an IC50 of 10 nM, it has >10 folds selectivity for PRMT6 over PRMT1 and PRMT8. EPZ020411 hydrochloride can be used for the research of cancer.
    EPZ020411 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity

EZH1

EZH2

DOT1L

SMYD2

SMYD3

SUV39H2/KMT1B

EHMT2/G9a/KMT1C

EHMT1/GLP/KMT1D

ASH1L/KMT2H

SETDB1/KMT2G

SETD2/KMT3A

NSD2/MMSET/WHSC1

SETD7/KMT7

SETD8/KMT5A

PRMT1

PRMT3

PRMT4

PRMT5

PRMT6

PRMT7

PRMT8

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Histone Methyltransferase Degraders & Inhibitors
Product NameEZH1EZH2DOT1LSMYD2SMYD3SUV39H2/KMT1BEHMT2/G9a/KMT1CEHMT1/GLP/KMT1DASH1L/KMT2HSETDB1/KMT2GSETD2/KMT3ANSD2/MMSET/WHSC1SETD7/KMT7SETD8/KMT5APRMT1PRMT3PRMT4PRMT5PRMT6PRMT7PRMT8Purity    
GSK126 
EZH2, IC50: 9.9 nM
                   99.98%
Tazemetostat 
EZH2
                   99.93%
Pinometostat  
DOT1L
                  99.99%
GSK3326595                 
PRMT5
   99.83%
3-Deazaneplanocin A hydrochloride 
EZH2
                   99.98%
NSD2-PWWP1-IN-1           
NSD2, IC50: 0.64 μM
         98.72%
NSD2-PWWP1-IN-2           
NSD2, IC50: 1.49 μM
         99.64%
NSD2-PWWP1-IN-3           
NSD2, IC50: 8.05 μM
         
GSK343 
EZH2
                   99.88%
EZM0414 TFA          
SETD2/KMT3A
          
BIX-01294      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             98.44%
Navlimetostat                 
PRMT5
   99.40%
UNC0642      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             99.92%
EPZ015666                 
PRMT5
   99.83%
MS023              
PRMT1
PRMT3
  
PRMT6
 
PRMT8
99.73%
Onametostat                 
PRMT5
   99.79%
SGC0946  
DOT1L, IC50: .3 nM
                  99.68%
EPZ004777  
DOT1L
                  99.00%
UNC1999
EZH1
EZH2
                   99.87%
3-Deazaneplanocin A 
EZH2
                   99.97%
UNC0638      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             99.05%
MS177 
EZH2
                   98.00%
Valemetostat
EZH1
                    99.84%
UNC0379             
SETD8/KMT5A
       99.90%
GSK591                 
PRMT5
   99.91%
TP-064                
PRMT4, IC50: <10 nM
 
PRMT6, IC50: 1300 μM
  99.61%
SGC707               
PRMT3, IC50: 31 nM
     98.08%
A-366      
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
             98.01%
UNC0224      
G9a, IC50: 15 nM
G9a, Ki: 2.6 nM
G9a, Kd: 23 nM
EHMT1/GLP/KMT1D, IC50: 20-58 nM
             98.85%
SETDB1-TTD-IN-1         
SETDB1/KMT2G
           99.93%
EZM0414          
SETD2/KMT3A
          99.11%
MS1943 
EZH2 methyltransferase, IC50: 120 nM
                   98.92%
CM-272      
G9a, IC50: 8 nM
EHMT1/GLP/KMT1D, IC50: 2 nM
             98.70%
SGC3027                   
PRMT7
 98.06%
A-395 
EZH2
                   99.12%
LLY-283                 
PRMT5
   99.22%
Ralometostat                 
PRMT5
   98.89%
AMI-1              
PRMT1
      ≥98.0%
PFI-2 hydrochloride            
SETD7/KMT7
        99.48%
EPZ020411              
PRMT1, IC50: 0.119 μM
   
PRMT6, IC50: 0.01 μM
 
PRMT8, IC50: 0.223 μM
98.07%
Valemetostat tosylate
EZH1
                    99.84%
AS-99 TFA        
ASH1L/KMT2H
            99.15%
EPZ-719          
SETD2/KMT3A
          99.85%
AZ505   
SMYD2
                 99.99%
EPZ020411 hydrochloride              
PRMT1, IC50: 0.119 μM
   
PRMT6, IC50: 0.01 μM
 
PRMT8, IC50: 0.223 μM
98.15%
BCI-121    
SMYD3
                99.26%
LLY-507   
SMYD2, IC50: <15 nM
                 98.28%
UNC0321      
G9a, Ki: 63 pM
G9a, IC50: 6-9 nM
EHMT1/GLP/KMT1D, IC50: 15-23 nM
             99.91%
EPZ031686    
SMYD3, IC50: 3 nM
                99.71%
PROTAC EZH2 Degrader-1 
EZH2, IC50: 2.7 nM
                   99.44%
UNC 0631      
G9a, IC50: 4 nM
              98.35%
EPZ011989 
EZH2
                   98.79%
TC-E 5003              
PRMT1
      98.03%
Furamidine dihydrochloride              
PRMT1
      ≥99.0%
SGC2085                
PRMT4
    99.46%
BVT948             
SETD8/KMT5A
       ≥99.0%
PF-06939999                 
PRMT5
   99.84%
MS4322
EZH1
EZH2
DOT1L
SMYD2
SMYD3
SUV39H2/KMT1B
EHMT2/G9a/KMT1C
EHMT1/GLP/KMT1D
 
SETDB1/KMT2G
SETD2/KMT3A
NSD2
SETD7/KMT7
SETD8/KMT5A
PRMT1
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
99.14%
Gambogenic acid 
EZH2
                   99.94%
PF-06726304 
EZH2 WT, Ki: 0.7 nM
EZH2 Y641N, Ki: 3.0 nM
                   98.37%
EPZ005687 
EZH2, Ki: 24 nM
                   99.46%
MS117                  
PRMT6
  ≥98.0%
BRD4770      
EHMT2/G9a/KMT1C
              99.69%
BAY-598   
SMYD2
                 99.30%
MS023 dihydrochloride              
PRMT1
PRMT3
  
PRMT6
 
PRMT8
99.30%
JQEZ5 
EZH2
                   98.08%
GSK503 
EZH2
                   99.52%
C-7280948              
PRMT1
      98.57%
Dot1L-IN-4  
DOT1L, IC50: 0.11 nM
                  99.54%
RK-701      
G9a, IC50: 23-27 nM
              98.04%
EI1 
EZH2 Y641F mutant type, IC50: 13 nM
EZH2 WT, EC50: 15 nM
                   99.78%
CARM1-IN-1                
PRMT4
    
MRTX9768                 
PRMT5
   99.60%
GSK2807 Trifluoroacetate    
SMYD3, Ki: 14 nM
SMYD3, IC50: 130 nM
                99.36%
BAY-6035    
SMYD3, IC50: 88 nM
                99.82%
NUCC-0226272 
EZH2
                   99.68%
UNC0646      
G9a, IC50: 6 nM
GLP, IC50: <15 nM
             99.38%
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH 
EZH2
                   99.06%
MS049                
PRMT4, : 34 nM
 
PRMT6, : 43 nM
 
PRMT8, : 1600 nM
≥98.0%
LLC0424           
NSD2, DC50: 20 nM
         98.42%
Tulmimetostat
EZH1
EZH2
                   99.79%
OTS193320     
SUV39H2/KMT1B
               98.64%
PRMT5-IN-25                 
PRMT5, Ki: 0.06 nM
   99.94%
AS-85        
ASH1L/KMT2H
            98.96%
EM127    
SMYD3
                98.37%
DCLX069              
PRMT1, IC50: 17.9 μM
      98.03%
HLCL-61 hydrochloride                 
PRMT5
   99.87%
AZ505 ditrifluoroacetate   
SMYD2
                 99.91%
DS-437                 
PRMT5
 
PRMT7
 98.00%
EHMT2-IN-1      
EHMT2 PEP, IC50: <100 nM
EHMT2 ICW, IC50: <100 nM
EHMTI PEP, IC50: <100 nM
             99.85%
BRD0639                 
PRMT5
   98.04%
EHMT2-IN-2      
EHMT2 PEP, IC50: <100 nM
EHMT2 ICW, IC50: <100 nM
EHMTI PEP, IC50: <100 nM
             ≥99.0%
MS8847 
EZH2
                   99.78%
Navlimetostat hydrochloride                 
PRMT5
   99.22%
MS8511      
G9a, IC50: 100 nM
G9a, Kd: 44 nM
GLP, IC50: 140 nM
GLP, Kd: 46 nM
             
BRD9539      
G9a, IC50: 6.3 μM
              99.74%
SMYD3-IN-1    
SMYD3, IC50: 11.7 nM
                98.01%
MS4322 (isomer)
EZH1
EZH2
DOT1L
SMYD2
SMYD3
SUV39H2/KMT1B
EHMT2/G9a/KMT1C
EHMTI PEP
 
SETDB1/KMT2G
SETD2/KMT3A
NSD2
SETD7/KMT7
SETD8/KMT5A
PRMT1
PRMT3
PRMT4
PRMT5
PRMT6
PRMT7
PRMT8
99.22%
EPIC-0628 
EZH2
                   98.93%
EZH2-IN-2 
EZH2, IC50: 64 nM
                   99.40%
CMP-5                 
PRMT5
   99.02%
GNA002 
EZH2, IC50: 1.1 μM
                   98.02%
Dot1L-IN-5  
DOT1L, IC50: 0.17 nM
                  99.82%
UNC2399 
EZH2, IC50: 17 nM
                   99.62%
PR5-LL-CM01                 
PRMT5
   98.45%
EBI-2511 
EZH2
                   99.81%
GSK3368715              
PRMT1
PRMT3
PRMT4
 
PRMT6
 
PRMT8
99.24%
CARM1-IN-1 hydrochloride                
PRMT4
    
DC-S239  
DOT1L
   
EHMT2/G9a/KMT1C
              99.43%
SETDB1-TTD-IN-1 TFA         
SETDB1/KMT2G
           99.77%
Tanshindiol C 
EZH2, IC50: 0.55 μM
                   98.47%
NSC745885 
EZH2
                   ≥98.0%
AZ506   
SMYD2, IC50: 17 nM
                 99.74%
ZZM-1220      
G9a, IC50: 458 nM
GLP, IC50: 924 nM
             98.74%
PRMT5-IN-30                 
PRMT5, IC50: 0.33 μM
PRMT5, Kd: 0.987 μM
   99.17%
EPZ011989 trifluoroacetate 
EZH2
                   98.71%
DW14800                 
PRMT5
   99.63%
CPUY074020      
EHMT2/G9a/KMT1C
              98.56%
Dot1L-IN-1 TFA  
DOT1L
                  98.56%
SGC8158                   
PRMT7
 
YM458 
EZH2, IC50: 490 nM
                   99.16%
(S)-HH2853 
EZH2 Y641N, IC50: <100 nM
                   
A-893   
SMYD2
                 
PRMT5-IN-1                 
PRMT5
   
AS-99 free base        
ASH1L/KMT2H
            
EML741      
G9a, IC50: 23 nM
G9a, Kd: 1.13 μM
              
MRTX9768 hydrochloride                 
PRMT5
   99.88%
PRMT5-IN-1 hydrochloride                 
PRMT5
   99.50%
PRMT5-IN-4                 
PRMT5
   ≥99.0%
PFI-2            
SETD7/KMT7
        
TDI-6118 
EZH2
                   
(R)-HH2853 
EZH2 Y641F mutant type, IC50: <100 nM
                   
BIX-01294 hydrochloride hydrate      
G9a, IC50: 1.7 μM
GLP, IC50: 38 μM
             
CPI-1328 
EZH2
                   
AS-99        
ASH1L/KMT2H
            
Dot1L-IN-1  
DOT1L
                  
PRMT5-IN-14                 
PRMT5
   
GSK3368715 trihydrochloride              
PRMT1, IC50: 3.1 nM
PRMT3, IC50: 48 nM
PRMT4, IC50: 1148 nM
 
PRMT6, IC50: 5.8 nM
 
PRMT8, IC50: 1.7 nM
PF-06726304 acetate 
EZH2 WT, Ki: 0.7 nM
EZH2 Y641N, Ki: 3.0 nM
                   
3-Deazaneplanocin A hydrochloride (GMP) 
EZH2
                   
IHMT-EZH2-426 
EZH2 WT, IC50: 1.3 nM
EZH2-A687V, IC50: 1.2 nM
Y641F/Y641N/Y641S, IC50: 1.7-3.5 nM
                   
PRMT5-MTA-IN-1                 
PRMT5
   
PRMT5-IN-39-d3                 
PRMT5
   
EZH2-IN-22 
EZH2 Y641N, IC50: <0.00051 μM
EZH2 Y641F mutant type, IC50: <0.00051 μM
EZH2 WT, IC50: 0.00052 μM
                   
BBDDL2059 
EZH2 Y641F mutant type, IC50: 1.5 nM
                   
PRMT5-IN-34                 
PRMT5
   
EZH2-IN-4 
WT 5-mer EZH2, IC50: 0.923 nM
mut 5-mer EZH2, IC50: 2.65 nM
                   
EZH2/HSP90-IN-29 
EZH2, IC50: 6.29 nM
                   
EZH2-IN-16 
EZH2 WT, IC50: 37.6 nM
EZH2 Y641F mutant type, IC50: 79.1 nM
                   
Dot1L-IN-9  
DOT1L, IC50: 125 nM
                  
HDACs/EZH2-IN-1 
EZH2 WT, IC50: 0.84 nM
EZH2 Y641N, IC50: 1.36 nM
                   
PRMT5-IN-28                 
PRMT5
   
PRMT4-IN-1              
PRMT1, IC50: 0.835 μM
PRMT3, IC50: 4.05 μM
PRMT4, IC50: 3.2 nM
PRMT5, IC50: 1.46 μM
PRMT6, IC50: 1.75 μM
PRMT7, IC50: 1.68 μM
PRMT8, IC50: 1.95 μM
CSV0C018875      
G9a
              
DM-01 
EZH2
                   98.03%
PARP/EZH2-IN-2 
EZH2, IC50: 27.34 ± 1. nM
                   
PRMT5-IN-47                 
PRMT5, IC50: 15 nM
   
PRMT5-IN-19              
PRMT1, IC50: 3.252 μM
 
PRMT4, IC50: >20 μM
PRMT5, IC50: 23.9 nM
   
EZH2-IN-5 
EZH2 WT, IC50: 1.52 nM
EZH2 Y641F mutant type, IC50: 4.07 nM
                   
Antitumor agent-101      
G9a, IC50: 8.5 nM
GLP, IC50: 5.5 nM
             
SMYD3-IN-2    
SMYD3, IC50: 0.81 μM μM
                
PARP/EZH2-IN-1 
EZH2, IC50: 36.51 nM
                   
PROTAC PRMT3 degrader 1               
PRMT3
     
W4275           
NSD2, IC50: 17 nM
         
(S)-Navlimetostat                 
PRMT5
   
PRMT5-IN-45                 
PRMT5, IC50: 3 nM
   
PRMT5-IN-43                 
PRMT5
   
PRMT3-IN-4               
PRMT3
     
PRMT5-IN-44                 
PRMT5
   
PRMT3-IN-5               
PRMT3, IC50: 261 nM
     
D-01 
EZH2, IC50: 0.99 μM
                   
PRMT5-IN-9                 
PRMT5, IC50: 0.01 μM
   
CARM1-IN-4              
PRMT1, IC50: 56 nM
PRMT3, IC50: 2637 nM
 
PRMT5, IC50: >100 (Pan)
PRMT6, IC50: 30 nM
 
PRMT8, IC50: 31 nM
Dot1L-IN-7  
DOT1L, IC50: 1 μM
                  
PRMT5-IN-23                 
PRMT5
   
UNC2327               
PRMT3
     99.70%
DCG066      
G9a
              99.78%
EZH2-IN-7 
EZH2
                   
AMI-408              
PRMT1
      
PRMT5-IN-49                 
PRMT5, IC50: > 100 μM
   
PRMT5-IN-33              
PRMT1, IC50: 6.89 μM
  
PRMT5, IC50: 10.9 nM
   
PRMT5-IN-21                 
PRMT5
   
PRMT5-IN-36-d3                 
PRMT5
   
EZH2-IN-19 
EZH2 WT, IC50: 0.32 nM
EZH2 Y641F mutant type, IC50: 0.03 nM
EZH2 Y641N, IC50: 0.08 nM
                   
MU1656  
DOT1L, IC50: 2 nM
                  
SGC2085 hydrochloride                  
PRMT6, IC50: 5.2 μM
  
EPZ0025654                  
PRMT6, IC50: 3 nM
  
GSK926 
EZH2, IC50: 0.02 μM
                   
DCE_42 
EZH2, IC50: 22.6 μM